Richard Leff
About Richard Leff
Richard Leff serves as the Chief Medical Officer at Conisus, LLC, where he has worked since 2008. He specializes in oncology and aims to improve therapies for patients through strategic planning.
Work at Conisus
Richard Leff has served as the Chief Medical Officer at Conisus, LLC since 2008. With over 16 years of experience in this role, he operates from the Greater Atlanta Area. His responsibilities include overseeing medical strategies and initiatives aimed at enhancing oncology therapies. Leff's focus is on bringing new and better treatments to oncology patients through effective strategic planning.
Previous Experience in Oncology
Before joining Conisus, Richard Leff held several significant positions in the oncology field. He worked as the Chief Information Officer and partner at Georgia Cancer Specialists from 1989 to 2004. Additionally, he served as the Chairman of Cancer Quality Improvement at DeKalb Medical Center from 1991 to 2004. Leff also held the role of Vice President for Clinical Operations at NMCR from 2004 to 2007.
Education and Expertise
Richard Leff earned his Doctor of Medicine (MD) degree from Brown Medical School, where he studied from 1976 to 1979. He also holds a Bachelor of Arts in Biomedical Ethics from Brown University, completed from 1972 to 1976. His educational background supports his unique expertise in interpreting and forecasting physician behavior within the oncology market.
Contributions to Oncology Discussions
Leff possesses extensive experience in moderating discussions among key opinion leaders and community specialists in the medical field. His role involves facilitating dialogue that aids in the development and implementation of oncology treatments. This experience enhances his ability to assist biotech and pharmaceutical firms in strategic planning to optimize existing oncology therapies.
Professional Goals
Richard Leff's professional goal centers on improving the therapeutic landscape for oncology patients. He aims to achieve this through strategic planning that focuses on the introduction of new therapies and the enhancement of existing treatment options in the oncology sector.